Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selegiline for Excessive Daytime Sleepiness in Parkinson’s Disease (Open Single-Arm Trial)
ChiCTR2100045946Phase 4Completed
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selegiline in Parkinson's disease (PD) and Excessive Daytime Sleepiness (EDS), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoint: Epworth Sleepiness Scale (ESS). Started Mar 2020; status: completed.
02
Drugs
selegiline
03
Conditions
Parkinson's disease (PD)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on ChiCTR2100045946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045946.